人肝癌细胞MHCC-97L组蛋白乙酰化位点修饰水平变化的研究

肝脏 ›› 2022, Vol. 27 ›› Issue (12): 1296-1299.

人肝癌细胞MHCC-97L组蛋白乙酰化位点修饰水平变化的研究

张建栋, 李梁和, 程海玉, 姜洞彬, 杨勤, 詹玮

550004 贵阳贵州医科大学临床医学院(张建栋,姜洞彬);贵州医科大学附属肿瘤医院胃肠外科(李梁和);贵州医科大学附属医院肛肠外科(程海玉,詹玮);贵州医科大学病理生理学教研室(杨勤)

收稿日期:2022-01-08 发布日期:2023-01-30
通讯作者: 詹玮,Email: 1564970707@qq.com
基金资助:
黔东南州科技计划项目(黔东南科合J字[2019]146号)

The changes of histone acetylation modification in low invasive hepatocellular carcinoma cells

ZHANG Jian-dong¹, LI Liang-he², CHENG Hai-yu³, JIANG Dong-bin¹, YANG Qin⁴, ZHAN Wei^3*

1. Clinical Medical School, Guizhou Medical University,Guiyang 550004,China;
2. Department of Gastrointestinal, Affiliated Tumor Hospital of Guizhou Medical University,Guiyang 550004,China;
3. Department of Anorectal,Affiliated Hospital of Guizhou Medical University, Guiyang 550004,China;
4. Department of Pathophysiology,Guizhou Medical University, Guiyang 550004, China

Received:2022-01-08 Published:2023-01-30
Contact: ZHAN Wei,Email: 1564970707@qq.com

摘要/Abstract

摘要： 目的探究人低转移性肝癌细胞株MHCC-97L组蛋白乙酰化位点修饰水平的变化情况,为临床肝癌的早期诊疗提供参考。方法检测人正常肝细胞株LO2及人低转移性肝癌细胞株MHCC-97L的增殖与凋亡情况;Western Blot法分析LO2及MHCC-97L细胞的acH3K14、acH3K18、acH3K27修饰的情况。结果 RTCA结果显示,培育48 h后人低转移性肝癌细胞株MHCC-97L增殖速度明显大于人正常肝细胞株LO2,且差异具有统计学意义(P<0.05);荧光显微镜下观察两种细胞株的凋亡情况差异不大;MHCC-97L细胞株组蛋白H3K14、H3K18、H3K27水平较LO2细胞株显著下调,差异有统计学意义(P<0.05)。结论低转移性肝癌细胞株MHCC-97L增殖速率显著高于正常的细胞株LO2,而自然凋亡率与正常细胞无差异,其组蛋白H3K14、H3K18及H3K27位点乙酰化修饰水平降低,这可能与肝癌的发生和发展具有一定的相关性,监测和提高肝癌细胞组蛋白乙酰化水平,或许对临床肝癌诊疗和药物开发具有参考价值。

关键词: 低转移性人肝癌细胞, 细胞增殖, 细胞凋亡, 组蛋白乙酰化

Abstract: Objective To investigate the changes of histone acetylation modification in normal hepatocyte line LO2 cells and low invasive hepatocellular carcinoma (HCC) line MHCC-97L cells.Methods The proliferation and apoptosis of LO2 and MHCC-97L cells were detected by real-time cell analysis (RTCA); the modification of acH3K14, acH3K18, acH3K27 in LO2 and MHCC-97L cells were analyzed by Western Blot.Results The results of RTCA showed that the proliferation rate of low invasive MHCC-97L cells was significantly higher than that of LO2 cells, of which the difference was statistically significant (P<0.05). There was little difference in apoptosis between the two cell lines under fluorescence microscope. The levels of acetylation modification of histone H3K14, H3K18, H3K27 in MHCC-97L cells were significantly lower than those in LO2 cells (P<0.05).Conclusion Compared to LO2 cells, the multiplication rate of MHCC-97L cells was significantly higher whereas the natural apoptosis rate was not different. The histone modification of acH3K14, acH3K18 and acH3K27 in MHCC-97L cells were decreased which might be associated with the hepatocarcinogenesis. Monitoring the levels of histone acetylation in hepatocytes may have a reference value for the clinical diagnosis of HCC and the upregulation of it may be a target for drug development against HCC.

Key words: Low invasive hepatocellular carcinoma cells, Proliferation, Apoptosis, Histone Acetylation

张建栋, 李梁和, 程海玉, 姜洞彬, 杨勤, 詹玮. 人肝癌细胞MHCC-97L组蛋白乙酰化位点修饰水平变化的研究[J]. 肝脏, 2022, 27(12): 1296-1299.

ZHANG Jian-dong, LI Liang-he, CHENG Hai-yu, JIANG Dong-bin, YANG Qin, ZHAN Wei. The changes of histone acetylation modification in low invasive hepatocellular carcinoma cells[J]. Chinese Hepatolgy, 2022, 27(12): 1296-1299.

参考文献

[1] Sarin SK, Kumar M, Eslam M, et al. Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.Lancet Gastroenterol Hepatol, 2020, 5(2):167-228.
[2] Chow AK, Yau SL, Ng L, et al. Novel molecular targets in hepatocellular carcinoma.World J Clin Oncol,2020,11(8):589-605.
[3] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin, 2018, 68(6):394-424.
[4] Zhu RX. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region.Gut Liver, 2016(3):332-339.
[5] 李梁和, 陈忠胜, 郑璐, 等. 结肠癌中相关组蛋白乙酰化修饰位点的机制探讨.贵州医药,2018,42(09):1031-1034.
[6] Chen J, Hu Y, Yu Y, et a1. Quantitative analysis of post-translational modifications of histone H3 variants during the cell cycle.Anal Chim Acta,2019,1080:116-126.
[7] Fu LN, Tan J, Chen YX, et a1. Genetic variants in the histone methylation and acetylation pathway and their risks in eight types of cancers.J Dig Dis,2018,19(2):102-111.
[8] Hałasa M, Wawruszak A, Przybyszewska A, et al. H3K18Ac as a Marker of Cancer Progression and Potential Target of Anti-Cancer Therapy.Cells,2019,8(5):485.
[9] Fernández-Barrena MG, Arechederra M, Colyn L, et al. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg.JHEP Rep,2020,2(6):100167.
[10] Yuan JH, Yang F, Chen BF, et al. The histone deacetylase 4/SP1/microrna-200a regulatory network contributes to aberrant histone acetylation in hepatocellular carcinoma.Hepatology,2011(6):2025-2035.
[11] Zhao J, Wozniak A, Adams A, et al.SIRT7 regulates hepatocellular carcinoma response to therapy by altering the p53-dependent cell death pathway.J Exp Clin Cancer Res,2019,38(1):252.
[12] Yu L, Xie R, Yang Q, et al. Suberoylanilide hydroxamic acid upregulates histone acetylation and activates endoplasmic reticulum stress to induce apoptosis in HepG2 liver cancer cells.Oncol Lett,2019,18(4):3537-3544.
[13] Liu KY, Wang LT, Hsu SH. Modification of Epigenetic Histone Acetylation in Hepatocellular Carcinoma.Cancers(Basel),2018,10(1):8.
[14] Zhang T, Zhao LL, Zeng SY, et al.UHRF2 decreases H3K9ac expression by interacting with it through the PHD and SRA/YDG domain in HepG2 hepatocellular carcinoma cells.International Journal of Molecular Medicine,2017,36(5):126-134.
[15] Wang WY, Xu LJ, Kong JL, et al. Quantitative research of histone H3 acetylation levels of human hepatocellular carcinoma cells.Bioanalysis,2013,5(3):327-339.
[16] Gambacorta V, Gnani D, Vago L, et al. Epigenetic Therapies for Acute Myeloid Leukemia and Their Immune-Related Effects.Front Cell Dev Biol,2019,7(12):207-213.
[17] Cai MY, Hou JH, Rao HL, et al. Identification of key genes and important histone modifications in hepatocellular carcinoma. Comput Struct Biotechnol J, 2020, 18(6):2657-2669.
[18] Hung SY, Lin HH, Yeh KT, et al. Histone-modifying genes as biomarkers in hepatocellular carcinoma.Int J Clin Exp Pathol, 2014, 7(5): 2496-2507.
[19] Lien HC, Jeng YM, Yuan RH, et al. Increased Trimethylation of histone H3K36 associates with biliary differentiation and predicts poor prognosis in resectable hepatocellular carcinoma. PLoS One, 2018,13(10):1-15.